Please assess the completion status of the following clinical trial:

Trial Title: PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A participant with primary, nodular BCC lesion(s) suitable for entry is defined as a participant with~* Clinically diagnosed primary nodular BCC lesion(s).~* Histologically confirmed diagnosis of BCC.~* BCC lesions suitable for simple excision surgery.~* Males or females above 18 years of age.~* Written informed consent.~Exclusion Criteria:~A participant that is ineligible for inclusion is a participant fulfilling any of the following criteria:~* Participants with porphyria.~* Participant with Gorlin's syndrome.~* Participant with Xeroderma pigmentosum.~* Participants concurrently receiving immunosuppressive medication.~* Participants with a history of arsenic exposure.~* Known allergy to Metvix®, a similar PDT compound or excipients of the cream.~* Participation in other clinical studies either concurrently or within the last 30 days.~* Pregnant or breast-feeding: All women of child-bearing potential must use adequate contraception (e.g. barrier methods, oral contraceptives or intrauterine device) during the treatment period and one month thereafter. In addition, they must have a negative pregnancy test prior to treatment.~* Conditions associated with a risk of poor protocol compliance.~Lesion Exclusion Criteria:~* A nodular BCC lesion in periorbital area, ears and nasolabial fold.~* A nodular BCC lesion with the longest diameter less than 6 mm or larger than 15 mm in face/scalp, larger than 20 mm on extremities and neck and larger than 30 mm on truncus.~* Pigmented nodular BCC lesion(s).~* Morpheaform nodular BCC lesion(s).~* Infiltrating nodular BCC lesion(s).~* Prior treatment of the BCC lesion(s).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metvix® cream 160 milligram per gram (Type: EXPERIMENTAL): Methyl aminolevulinate hydrochloride 160 milligram (mg)/gram (g) cream were received by participants with primary nodular basal cell carcinoma. A thick layer of study cream was applied directly on the lesion and on 5 mm of the surrounding tissue. An approximately 1 mm thick layer of cream was applied to cover the lesion completely. The study cream was applied for at least 3 hours followed by illumination using non-coherent red (570-670 nm) light at a fluence of 50- 75 J/cm\^2.
- Placebo (Type: PLACEBO_COMPARATOR): Participants with primary nodular basal cell carcinoma received Metvix® matching placebo cream. A thick layer of study cream was applied directly on the lesion and on 5 mm of the surrounding tissue. An approximately 1 mm thick layer of cream was applied to cover the lesion completely. The study cream was applied for at least 3 hours followed by illumination using non-coherent red (570-670 nm) light at a fluence of 50- 75 J/cm\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).